TY - JOUR
T1 - Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis
AU - Sellebjerg, F
AU - Christiansen, M
AU - Jensen, J
AU - Frederiksen, J L
PY - 2000/5
Y1 - 2000/5
N2 - The immunological effects of high-dose methylprednisolone in attacks of multiple sclerosis and acute optic neuritis have only been examined in a few randomized, controlled trials. We studied immunological changes in 50 patients with optic neuritis or multiple sclerosis who underwent lumbar puncture before and 1 week after completing a 15-day course of oral high-dose methylprednisolone treatment. Treatment resulted in a decrease in the concentration of myelin basic protein, a decrease in the serum concentration of immunoglobulin G (IgG) and intrathecal IgG synthesis, an increase in the cerebrospinal fluid concentration of transforming growth factor-beta1, and changes in the expression of CD25, CD26, and human leukocyte antigen-DR (HLA-DR) on CD4 T-cells. No effect was seen on the cerebrospinal fluid leucocyte count or the cerebrospinal fluid activity of matrix metalloproteinase-9 (MMP-9). The lack of a persistent effect on cerebrospinal fluid leucocyte recruitment and MMP-9 activity, despite changes in IgG synthesis, T-cell activation, and cytokine production, suggests that modulation of the function of inflammatory cells may contribute to the clinical efficacy of oral high-dose methylprednisolone treatment in optic neuritis and multiple sclerosis.
AB - The immunological effects of high-dose methylprednisolone in attacks of multiple sclerosis and acute optic neuritis have only been examined in a few randomized, controlled trials. We studied immunological changes in 50 patients with optic neuritis or multiple sclerosis who underwent lumbar puncture before and 1 week after completing a 15-day course of oral high-dose methylprednisolone treatment. Treatment resulted in a decrease in the concentration of myelin basic protein, a decrease in the serum concentration of immunoglobulin G (IgG) and intrathecal IgG synthesis, an increase in the cerebrospinal fluid concentration of transforming growth factor-beta1, and changes in the expression of CD25, CD26, and human leukocyte antigen-DR (HLA-DR) on CD4 T-cells. No effect was seen on the cerebrospinal fluid leucocyte count or the cerebrospinal fluid activity of matrix metalloproteinase-9 (MMP-9). The lack of a persistent effect on cerebrospinal fluid leucocyte recruitment and MMP-9 activity, despite changes in IgG synthesis, T-cell activation, and cytokine production, suggests that modulation of the function of inflammatory cells may contribute to the clinical efficacy of oral high-dose methylprednisolone treatment in optic neuritis and multiple sclerosis.
KW - Acute Disease
KW - Administration, Oral
KW - Adult
KW - Anti-Inflammatory Agents/administration & dosage
KW - Antigens/blood
KW - CD4-Positive T-Lymphocytes/immunology
KW - Dose-Response Relationship, Drug
KW - Female
KW - Flow Cytometry
KW - Humans
KW - Immune System/drug effects
KW - Immunoglobulin G/biosynthesis
KW - Leukocyte Count/drug effects
KW - Male
KW - Matrix Metalloproteinase 9/drug effects
KW - Methylprednisolone/administration & dosage
KW - Multiple Sclerosis/drug therapy
KW - Myelin Basic Protein/cerebrospinal fluid
KW - Optic Neuritis/drug therapy
KW - Randomized Controlled Trials as Topic
KW - Spinal Cord/metabolism
KW - Spinal Puncture
KW - Transforming Growth Factor beta/cerebrospinal fluid
U2 - 10.1046/j.1468-1331.2000.00074.x
DO - 10.1046/j.1468-1331.2000.00074.x
M3 - Journal article
C2 - 10886311
SN - 1351-5101
VL - 7
SP - 281
EP - 289
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 3
ER -